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Abstract
Background: Treatment of schizophrenia frequently includes prolonged benzodiazepine administration despite a
lack of evidence of its use. It is often difficult to discontinue benzodiazepines because of the development of
dependence. We aim to assess if melatonin can facilitate the withdrawal of prolonged benzodiazepine
administration in patients with schizophrenia. Furthermore, we aim to investigate the association of
benzodiazepine dose reduction with the following clinically important variables: sleep, psychophysiology, cognition,
social function, and quality of life.
Methods/Design: Randomized, blinded, two-armed, parallel superiority trial. We plan to include 80 consenting
outpatients diagnosed with schizophrenia or schizoaffective disorder, 18-55 years of age, treated with antipsychotic
drug(s) and at least one benzodiazepine derivative for the last three months before inclusion. Exclusion criteria:
currently under treatment for alcohol or drug abuse, aggressive or violent behavior, known mental retardation,
pervasive developmental disorder, dementia, epilepsy, terminal illness, severe co morbidity, inability to understand
Danish, allergy to melatonin, lactose, starch, gelatin, or talc, hepatic impairment, pregnancy or nursing, or lack of
informed consent. After being randomized to prolonged-release melatonin (Circadin
®) 2 mg daily or matching
placebo, participants are required to slowly taper off their benzodiazepine dose. The primary outcome measure is
benzodiazepine dose at 6 months follow-up. Secondary outcome measures include sleep, psychophysiological, and
neurocognitive measures. Data are collected at baseline and at 6 months follow-up regarding medical treatment,
cognition, psychophysiology, sleep, laboratory tests, adverse events, psychopathology, social function, and quality
of life. Data on medical treatment, cognition, psychophysiology, adverse events, social function, and quality of life
are also collected at 2 and 4 months follow-up.
Discussion: The results from this trial will examine whether melatonin has a role in withdrawing long-term
benzodiazepine administration in schizophrenia patients. This group of patients is difficult to treat and therefore
often subject to polypharmacy which may play a role in the reduced life expectancy of patients compared to the
background population. The results will also provide new information on the association of chronic
benzodiazepine treatment with sleep, psychophysiology, cognition, social function, and quality of life. Knowledge
of these important clinical aspects is lacking in this group of patients.
Trial Registration: ClinicalTrials NCT01431092
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Schizophrenia is one of the most costly brain diseases in
the world regarding human, social, and health economic
costs. The lifetime risk of developing schizophrenia is
0.7% and the prevalence is 0.5% [1]. The disease most
often manifests itself in late adolescence or early adult-
hood and often implies loss of social functioning and
reduced quality of life. Schizophrenia is a severe brain
disease with a heterogeneous course: 25-30% present a
mild course with almost full remission, 50% have a
moderate course with waxing and waning symptoms,
and 20-25% have chronic symptoms [2].
There has been an intense search for more effective
medical treatments, especially regarding the improve-
ment of cognitive functioning, which has been shown to
strongly predict the prognosis [3]. The second genera-
tion antipsychotics have been most intensively studied
with respect to these outcomes, because they were initi-
ally marketed as a revolution in the treatment including
the cognitive deficits. However, later trials have shown
that the pro-cognitive effect of these drugs is much
more modest than previously assumed [4,5].
Combination therapy with antipsychotics and other
classes of psychoactive drugs is highly prevalent in the
treatment of schizophrenia, but the effect on cognition
after long-term combination treatment has hardly been
investigated. The evidence available on augmentation of
antipsychotics with benzodiazepines is inconclusive [6];
nevertheless, benzodiazepine administration is often pro-
longed in patients with schizophrenia. Prolonged benzo-
diazepine administration is associated with numerous
adverse reactions including sedation, cognitive impair-
ment, risk of falls, development of tolerance, physical and
psychological dependence, and rebound insomnia
(reduced total sleep time and increased sleep latency when
treatment discontinues). Because of the development of
dependence, it is often difficult to discontinue long-term
benzodiazepine administration. Furthermore, we have
recently reported an association of increased risk of death
in schizophrenia patients treated with a combination of
antipsychotics and long-acting benzodiazepines [7]. This
underlines our poor understanding of potential interac-
tions and adverse reactions when benzodiazepines are
administered in combination with antipsychotic treatment.
Benzodiazepines demonstrate a high level of efficacy in
the initial treatment of insomnia, but several studies have
found changes in the sleep architecture (including
reduced amount of slow wave sleep), indicating reduced
sleep quality [8,9]. The effect on the sleep pattern follow-
ing long-term administration has not been investigated
but is highly important for patients with schizophrenia
since their sleep pattern is most often already disrupted.
According to systematic reviews, the majority of patients
with schizophrenia suffer from disturbed sleep, including
reduced sleep efficiency and total sleep time, increased
sleep latency, and changes in the sleep architecture,
including reduced amount of slow wave sleep and REM
(rapid eye movement) sleep [10,11].
Melatonin represents a possible alternative to treat
sleep disturbances in psychiatric patients with chrono-
biological disturbances [12]. A smaller observational
study has suggested that patients with schizophrenia
have reduced secretion of melatonin compared to
healthy controls [13]. In addition, benzodiazepine treat-
ment is associated with reduced secretion of melatonin
[14]. The drug is a naturally occurring hormone with
minimal adverse effects [15,16] and several possible
therapeutic effects, including sleep regulatory, anti-
inflammatory, neuroprotective, and pro-cognitive prop-
erties [12]. The effect of exogenous melatonin on these
outcomes in patients with schizophrenia has only been
investigated to a limited extent [17,18]. In a randomized,
blinded, cross-over trial, Shamir et al. found that mela-
tonin improved sleep efficiency in 19 patients with schi-
zophrenia and poor quality of sleep [17]. Kumar et al.
have shown that melatonin improved the quality of
sleep in a randomized, double-blinded, placebo-con-
trolled trial with 40 participants with schizophrenia [18].
Shamir et al. evaluated sleep quality from wrist actigra-
phy whereas Kumar et al. evaluated sleep quality subjec-
tively using a questionnaire.
The possibility of facilitating benzodiazepine withdra-
wal with temporary addition of melatonin has not been
addressed in patients with schizophrenia. However, in
general practice settings two randomized, placebo-con-
trolled trials with respectively 34 and 38 participants
(with insomnia not associated with schizophrenia)
reported contradictory results [19,20]. Garfinkel et al.
[19] found a statistically significant positive effect of
adding melatonin when tapering off benzodiazepines,
but they did not include a control of compliance (e.g.
urine screens). Vissers et al. [20] found no effect of mel-
atonin on the rate of benzodiazepine tapering. The two
trials both applied rather fast taper off regimens and a
limited amount of personal contact and support.
Because of the specific characteristics of schizophrenia
outlined above and the contradicting results in normal
participants, such results cannot readily be transferred
to schizophrenia patients.
Here we describe the design of a trial evaluating
whether prolonged-release melatonin is helpful in stop-
ping the long-term use of benzodiazepines in patients
with schizophrenia - the SMART trial.
Melatonin
Melatonin is a naturally occurring hormone produced
by the pineal gland and is structurally related to seroto-
nin. Physiologically, melatonin secretion increases soon
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diminishes during the second half of the night [21]. It is
the effect on melatonin receptors (MT1 and MT2) in
the suprachiasmatic nucleus in the hypothalamus which
contributes to the sleep inducing properties, because
these receptors are involved in the regulation of sleep
and circadian rhythms [22]. Melatonin has a very short
half-life (30-40 minutes) and the physiological level dur-
ing the night is maintained by continuous secretion.
Circadin
® is prolonged-release melatonin and is approved
as a drug in Europe for primary insomnia in patients aged
55 years or above. The physiological profile and levels of
melatonin is mimicked during 8-10 hours following oral
administration [23]. Each tablet contains 2 mg melatonin
and 80 mg lactose monohydrate. The tablets must be swal-
lowed in one piece 1-2 hours before bedtime and following
a meal. Circadin
® is not recommended for patients with
hepatic impairment [21]. Circadin
® is completely absorbed
after oral administration. The bioavailability is 15% because
of a pronounced first-pass effect in the liver.
The absorption is delayed when Circadin
® is ingested
with a meal resulting in delayed (3 hours versus 0.75
hours) and reduced peak plasma concentration [21].
The elimination half-life is 3.5-4 hours. The drug is
metabolized in the liver (the CYP1A enzymes and the
CYP2C19 enzyme), mostly to the inactive metabolite 6-
sulphatoxy-melatonin (6-S-MT), and eliminated by renal
excretion as sulphated and glucuronidated conjugates of
6-hydroxy melatonin [21].
T h ee f f i c a c yo fC i r c a d i n
® 2 mg has been investigated
in three randomized, blinded, placebo-controlled trials
lasting between 5 weeks and 6 months with respectively
170, 332, and 791 participants diagnosed with primary
insomnia [23-25]. An improved sleep quality and morn-
ing vigilance and reduced sleep latency compared with
placebo was reported in participants aged 55 years or
above. Trials comparing Circadin
® directly with a rele-
vant active comparator are lacking.
Research objectives and hypotheses
The SMART trial evaluates if prolonged-release melato-
nin versus placebo administration facilitates benzodiaze-
pine withdrawal in schizophrenia patients. We
hypothesize that adding melatonin will accelerate the
rate of benzodiazepine tapering off and therefore will
result in reduced benzodiazepine dose at follow-up in
the experimental group compared with the control
group. Furthermore, we aim to investigate how the
treatment affects cognition, sleep efficiency, and benzo-
diazepine withdrawal symptoms. Neurocognitive tests
and psychophysiological examinations are used to evalu-
ate the effect on cognition. Polysomnography is used to
evaluate the effect on sleep continuity and sleep archi-
tecture, and wrist actigraphy is applied to ensure that
the polysomnographical results are representative. We
also hypothesize that melatonin will improve cognition
reflected as improvements in neurocognitive and psy-
chophysiological measures; that melatonin will improve
sleep efficiency and subjective sleep quality; and that
melatonin will reduce withdrawal symptoms.
In addition, the data of the trial are also analyzed as
an observational cohort design to investigate the asso-
ciation of benzodiazepine dose reduction/discontinua-
tion with sleep, psychophysiology, cognition, social
function, and quality of life (further elaborated in
Appendix 1). These supplementary analyses will contri-
bute with important knowledge of the association
between benzodiazepine withdrawal in schizophrenia
and these outcomes, which eventually could lead to
more differentiated clinical treatment guidelines.
Methods/Design
Design
Randomized, blinded, two-armed, parallel group super-
iority trial (Figure 1).
Ethics
The trial has been approved by the Committee on Bio-
medical Research Ethics of The Capital Region in Den-
mark (H-1-2011-025) and the Danish Medicines Agency
(EudraCT 2010-024065-46) and is registered at Clinical-
Trials.gov (NCT01431092). The trial will be conducted
in accordance with the latest version of the Declaration
of Helsinki [26] and the International Conference on
Harmonization (ICH) - Good Clinical Practice (GCP)
guidelines for clinical trials [27]. The trial will be moni-
t o r e db yt h eG C PU n i ta tC o p e n h a g e nU n i v e r s i t y
Hospital.
Participants
Participants will be recruited from outpatient clinics
under the Mental Health Services in the Capital Region
of Denmark. In case of recruitment difficulties the inclu-
sion area can be extended to Region Zealand.
Inclusion criteria
￿ Patients diagnosed with schizophrenia or schizoaf-
fective disorder (ICD-10 (International Classification
of Diseases, 10
th edition) criteria for schizophrenia
(F20) or schizoaffective disorder (F25) must be ful-
filled at inclusion or previously as documented by
chart review; fulfillment of relevant DSM-IV-TR
(Diagnostic and Statistical Manual of Mental Disor-
ders, 4
th edition, text revision) criteria will also be
registered).
￿ Attached as outpatient to the Mental Health Ser-
vices of the Capital Region of Denmark or Region
Zealand (in case of recruitment difficulties).
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least 3 months before inclusion (change of dose,
antipsychotic polypharmacy, and prescription/dis-
continuation of add-on drugs are allowed but the
basic antipsychotic drug must have remained the
same).
￿ Benzodiazepine derivative administration (at least
one of: chlordiazepoxide, diazepam, clobazam,
clonazepam, flunitrazepam, nitrazepam, bromaze-
pam, alprazolam, lorazepam, lormetazepam, oxaze-
pam, or triazolam) for at least 3 months before
inclusion. Treatment with benzodiazepine-related
drugs (zolpidem, zopiclone, zaleplon) is not suffi-
c i e n tt ob ei n c l u d e di nt h et r i a lb u tt h e s ed r u g sw i l l
be included in the taper process.
￿ Age 18-55 years (both inclusive).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Enrollment 
Assessed for eligibility (n=  ) 
Excluded  (n=   ) 
i   Not meeting inclusion criteria (n=  ) 
i   Declined to participate (n=  ) 
i   Other reasons (n=  ) 
Randomized (n= 80) 
Allocated to placebo and gradual 
benzodiazepine withdrawal (n=  ) 
i Received allocated intervention (n=  ) 
i Did not receive allocated intervention (n=  ), 
reasons: 
Allocated to melatonin and gradual 
benzodiazepine withdrawal (n=  ) 
i Received allocated intervention (n=  ) 
i Did not receive allocated intervention (n=  ), 
reasons: 
Allocation 
Lost to follow-up (n=  ), 
 reasons: 
Discontinued intervention (n=  ), 
reasons: 
Lost to follow-up (n=  ),  
reasons: 
Discontinued intervention (n=  ), 
reasons: 
6 months follow-up 
Analyzed  (n=  ) 
i Excluded from analysis (n=  ) 
reasons: 
Analyzed  (n=  ) 
i Excluded from analysis (n=  ) 
reasons: 
Analysis 
Possible run-in phase  
Included (n=   ) 
Excluded  (n=   ) 
i   Declined to participate further (n=  ) 
i   Other reasons (n=  ) 
Figure 1 Flow chart of the SMART trial design.
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and the use of safe contraceptives (intrauterine
devices or hormonal contraception) throughout the
trial period and 1 day after withdrawal of trial medi-
cation. This does not apply to sterile or infertile par-
ticipants, i.e. surgically sterilized or post menopausal
women.
￿ Written informed consent.
Exclusion criteria
￿ Currently under treatment for abuse of alcohol or
drugs.
￿ Known aggressive or violent behavior.
￿ Known mental retardation, pervasive developmen-
tal disorder, or dementia.
￿ Epilepsy, terminal illness, severe co morbidity, or
unable to understand Danish.
￿ Allergy to compounds in the trial medication (mel-
atonin, lactose, starch, gelatin, and talc).
￿ Hepatic impairment (known diagnosis).
￿ Pregnancy or nursing.
￿ Lack of informed consent.
Experimental intervention and comparison
All trial participants are gradually tapered off their usual
benzodiazepine treatment (including benzodiazepine-
related drugs) following general national treatment
guidelines (Institute for Rational Pharmacotherapy, IRF)
[28], i.e. 10-20% dose reduction every week or every two
weeks. Gradual taper is preferred to sudden discontinua-
tion both nationally and internationally and this
approach is also supported by a Cochrane review [29].
The largest (percentage) dose reduction should be
planned during the beginning of the tapering process
where it is most easily tolerated. When treated with
short-acting benzodiazepine derivatives (elimination
half-life 24 hours or less) the participants are offered to
shift to diazepam (run-in phase). Diazepam is preferred
for tapering because of its long elimination half-life (and
therefore a stable plasma concentration) plus the avail-
ability of low dose tablets. If preferred by the individual
participant the tapering process will be conducted with
his/her usual benzodiazepine derivative. Participants
driving a car will not be offered to shift to diazepam
because of the long elimination half-life. Participants
will be advised not to drink alcohol during the trial per-
iod. The discontinuation plan will continuously be
adjusted according to the individual participant. If
necessary, the discontinuation can be (temporarily)
paused. There is no upper limit of the duration of stay-
ing on the same dose. The continuous contact with the
participants will follow general recommendations in this
area based on thorough clinical experience [30-32].
However, most current recommendations stem from
general practice [33].
Trial medication (Circadin
® 2 mg and matching placebo,
respectively) begins simultaneously with the tapering pro-
cess. The participants are instructed to ingest the trial medi-
cation 2 hours before bedtime (between 9 and 11 p.m.)
following a light meal. The participants are randomized and
given the trial medication once they are ready to begin
tapering off their benzodiazepine(s), i.e. after baseline
assessments and after possible shifting to long-acting ben-
zodiazepine (if the latter is relevant). The participants are
treated with the trial medication during the entire trial per-
iod including during the follow-up assessment after 6
months, irrespective of their final dose of benzodiazepine.
Hereafter, the trial medication is abruptly discontinued.
Any co medication is allowed. We aim to keep the co
medication constant during the trial period but any
necessary changes (from a clinical point of view) are
allowed and will be controlled for in the analysis if
necessary. It is possible that the withdrawal process will
reveal symptoms and signs (e.g. anxiety disorder, depres-
sion) where treatment with other non-dependence-pro-
ducing medication is indicated (e.g. antidepressant
drugs) [30]. The participants will continue in the trial
despite such medication changes.
Outcome measures and assessments
Primary outcome measure
￿ Benzodiazepine (including benzodiazepine related
drugs) dose at 6 months follow-up.
Secondary outcome measures
￿ Pattern of benzodiazepine dose over time (see sta-
tistical methods).
￿ The fraction of participants who has completely
discontinued benzodiazepines 6 months after initiat-
ing trial medication.
￿ Psychophysiology: Selective attention expressed as
P300 amplitude [34,35]. Pattern of P300 amplitude
over time is analyzed.
￿ Neurocognitive assessment: Brief Assessment of
C o g n i t i o ni nS c h i z o p h r e n i a( B A C S )c o m p o s i t es c o r e
[36]. Pattern of BACS score over time is analyzed.
￿ Sleep evaluation (one night polysomnography
(PSG) [37] conducted at home): Sleep efficiency at 6
months follow-up.
To evaluate if this single night PSG is representative
(irregular sleep patterns are expected), supplemen-
tary wrist actigraphy [38] is performed for 3 conse-
cutive days and nights.
￿ Subjective assessment of sleep quality: Pittsburgh
Sleep Quality Index (PSQI) global score [39] at 6
months follow-up.
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pine Withdrawal Symptom Questionnaire (BWSQ-2)
[40,41]. Pattern over time is analyzed.
Other variables measured to evaluate adverse events/
adverse reactions of the trial medication
￿ Clinical laboratory tests: Fasting blood glucose,
fasting lipid panel, haematology, serum chemistry
(sodium, potassium, creatinine, calcium, alanine
transaminase, alkaline phosphatase, and international
normalized ratio). An abnormal value (outside the
reference interval) will only be registered as an
adverse event if it was not present at baseline and if
an intervention is required to correct the value (e.g.
initiating treatment, referring the participant to
further examinations).
￿ Physical examination including blood pressure,
weight, height, waist circumference, and electrocardio-
gram. An abnormal result will only be registered as an
adverse event if it was not present at baseline and if an
intervention is required to correct the abnormality.
￿ Adverse events (AEs), serious adverse events
(SAEs), and suspected unexpected serious adverse
reactions (SUSARs) are registered at 2, 4, and 6
months follow-up or whenever occurring. AEs are
defined as any adverse change in health occurring
during the trial reported by the participants on
request. Date of occurrence and duration of each AE
is registered along with a clinical evaluation of its
possible relation to the trial medication. AEs are not
registered after the trial period (i.e. the last visit for
each participant). A SAE is defined as any untoward
medical occurrence that results in death, is life-
threatening, requires inpatient hospitalization or pro-
longation of existing hospitalization, results in per-
sistent or significant disability/incapacity, is a
congenital anomaly/birth defect, or requires inter-
vention to prevent permanent impairment or
damage. SUSARs are unexpected SAEs judged to be
related to the trial medication. Preplanned hospitali-
zations during the trial period and symptoms
undoubtedly attributable to benzodiazepine withdra-
wal will not be registered as AEs.
Other variables measured at baseline to characterize the
participants
￿ Age, sex, diagnosis, age at illness onset, illness
duration, and co morbidity.
￿ Sociodemographic characteristics (education, job,
marital status, family, housing), ethnicity, and
handedness.
In addition, we measure the plasma concentration of
benzodiazepines at 6 months follow-up to confirm the
compliance of the participants reporting complete ben-
zodiazepine discontinuation. Any co medication is regis-
tered at baseline and at 2, 4, and 6 months follow-up.
Baseline assessments are performed after inclusion and
before run-in (if relevant) and randomization. Follow-up
assessments are performed 6 months after initiating
withdrawal and trial medication. Several of the assess-
ments are also performed at 2 and 4 months (See Table
1 for summary of data collection).
Randomization
Central randomization is performed by the Copenhagen
Trial Unit (CTU) with computer generated, permuted
randomization allocation sequence with block size
unknown to the investigator. The investigator (or other
research staff) will call the CTU and provide a personal
pin code, participant civil registration and identification
number, and the value of the stratification variable of
benzodiazepine dose (low (≤15 mg diazepam equiva-
lents) versus high (>15 mg diazepam equivalents)) at
Table 1 Collection of data
Baseline 2
months*
4
months*
6
months*
Benzodiazepines (dose) X X X X
Co medication X X X X
Neurocognition (BACS) X X X X
Psychophysiology X X X X
Sleep assessment (PSG) X X
Psychopathology (PANSS) X X
Quality of life (WHO-5 and
SWN-S)
XXXX
Withdrawal symptoms
(BWSQ-2)
XXXX
Subjective sleep quality
(PSQI)
XX
Social functioning (PSP) X X X X
Laboratory tests X X
Lifestyle factors X X
Physical examination X X
Sociodemographic
characteristics
X
Plasma benzodiazepines X
Adverse events X X X
*After initiating trial medication and benzodiazepine withdrawal.
BACS: Brief Assessment of Cognition in Schizophrenia
PSG: Polysomnography
PANSS: Positive and Negative Syndrome Scale
WHO-5: WHO-5 Well-Being Scale
SWN-S: Subjective Well-being under Neuroleptic Treatment scale (short form)
BWSQ-2: Benzodiazepine Withdrawal Symptom Questionnaire
PSQI: Pittsburgh Sleep Quality Index
PSP: Personal and Social Performance Scale
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a trial medication package number.
Blinding
T r i a lp a r t i c i p a n t sa sw e l la st rial staff are blinded to the
allocated treatment. The blinding will be maintained by
using matching placebo, and an independent unit to per-
form the randomization and do the packaging and label-
ing of the trial medication. Both Circadin and placebo
are encapsulated in lactose containing gelatin capsules to
optimize the blinding. CTU holds the randomization
code which will not be broken until all data are regis-
tered, all analyses finished, and conclusions drawn [42].
The randomization code will only be broken during the
trial period in case of emergency if the investigator deci-
des that knowledge about the trial medication will affect
the treatment of a SAE or in case of a SUSAR. Blinded
data will be handed over to the CTU, which will be in
charge of double data entry and which will conduct the
statistical analyses blinded to the intervention.
Statistical analysis
The efficacy of the intervention with respect to benzo-
diazepine dose, sleep efficiency, and PSQI at 6 months
follow-up is analyzed using the univariate general linear
model with the outcome measure (6 months value) as
the dependent variable and the indicator of intervention
and the baseline value as the independent variables. If
the assumptions of the model cannot be fulfilled either
directly or after transformation a non-parametric
method will be used.
The efficacy of the intervention with respect to the frac-
tion of participants who completes the benzodiazepine
withdrawal (follow-up dose: 0) is analyzed using a logistic
regression model where logit(p) is the dependent variable, p
is the probability of completing the withdrawal, and a bin-
ary intervention indicator is the independent variable [43].
The effect of the intervention on the pattern of benzo-
diazepine dose, P300, BACS, and BWSQ-2 over time is
analyzed in a model describing outcome measure as a
function of time (2, 4, and 6 months after withdrawal
was initiated):
Without the intervention indicator the model can be
described as:
Outcome measure = int + baseline + a · t+b· t2 +c· baseline · t+d· baseline · t2
where int is the intercept, t is the independent variable
time, baseline is the baseline value of the outcome mea-
sure, and a through d are the coefficients of the func-
tion. The model is expanded to include a binary
indicator of intervention to test the overall effect of
intervention and its main effect and interaction with
time and time squared. In the analysis of the pattern of
benzodiazepine dose, P300, BACS, and BWSQ-2 over
time, we will apply a mixed model with repeated mea-
sures (MMRM). Using the Akaike’s criterion, we will
determine which co-variance structure fits the data the
best: an unstructured (un), a compound symmetric (cs),
or a first order autoregressive AR(1) with and without
variance heterogeneity. Time is included as a continuous
variable and sequential hypothesis testing will be applied
[44].
Missing values
Missing values will not lead to bias when the MMRM is
applied if data is missing at random which is not a very
rigorous condition. Provided significant results are
obtained using any of the above described methods, the
potential influence of values not missing at random will
be assessed for most outcome measures in a sensitivity
analysis. Let BEST be the group where a significant and
beneficial effect has been observed. Missing values will
be replaced by optimistic ones in the other group and
by pessimistic ones in BEST. Optimistic and pessimistic
values are inferred as follows:
￿ Dose after 2, 4, and 6 months: Pessimistic values
will be imputed as follows: Data will be reviewed
from left to right setting the 2 months value, if it is
missing, to equal the baseline value. If the 4 or 6
months value is missing it will be set to equal the pre-
ceding value (which may be an imputed one). When
imputing optimistic values, the data will be reviewed
from right to left setting the 6 months value to 0 if it
is missing. A missing 4 months as well as a missing 2
months value will be imputed with the subsequent
value (which may be an imputed one).
￿ Withdrawal completion: “Yes” is an optimistic
value and “no” is a pessimistic value.
￿ Continuous outcome measures only assessed after
6 months: An optimistic value equals the highest
v a l u ei nt h ew h o l es a m p l ea n dap e s s i m i s t i cv a l u e
the lowest value, if increasing the outcome measure
is considered beneficial. Vice versa if decreasing the
outcome measure is considered beneficial. Using
min and max of delta of the whole material pessi-
mistic and optimistic baseline values are constructed
by extrapolating from the 6 months value.
￿ For other analyses using the above mixed model
the sensitivity analysis will include a worst case ana-
lysis following the same technique as previously pub-
lished [45].
We do not plan any interim analysis because we do
not foresee any circumstances that should lead to clos-
ing the whole trial prematurely.
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Data directly illustrating the distribution of benzodiaze-
pine dose in patients with schizophrenia after going
through a discontinuation trial is not available in the lit-
erature. In the following we apply our own unpublished
data from a comprehensive chart review including regis-
tration of benzodiazepine dose in 99 consecutive outpa-
tients diagnosed with schizophrenia.
We assume that the trial participant, after having fol-
lowed a discontinuation plan for a certain period of
time, either has completed the withdrawal (intake of
benzodiazepines stopped) or has paused the gradual
taper and continues on a reduced dose. During the
taper off, we assume that the dose decay curve approxi-
mately follows an exponential function, because the dis-
continuation plan assumes a constant withdrawal rate. If
we know the dose at baseline, the rate of withdrawal
(slope), and the time of stopping the withdrawal (t), we
can calculate the final dose for each participant as
EXP(ln(baseline dose) - slope · t)
We further assume that the participant must follow
the discontinuation plan for 25 weeks to have com-
p l e t e dt h ed i s c o n t i n u a t i o n .W ew i s ht ob ea b l et o
detect a statistically significant difference of minimum
8 weeks between the two intervention groups with
regard to average duration of adherence to the discon-
tinuation plan with 90% probability. We furthermore
assume that the participants in the control group on
average will be able to follow the discontinuation plan
for two months (8 weeks) while the participants in the
melatonin group are assumed to be able to follow the
discontinuation plan for four months (16 weeks). The
slope is assumed to vary between 10 and 20% per
week in both groups.
The distribution of benzodiazepine dose in the mela-
tonin and placebo group is assumed to equal the distri-
bution found among our previous sample of outpatients.
The distribution of the final dose under the given
assumptions is therefore found as follows:
For each intervention group the slope is assumed to
follow an even distribution between 0.1 and 0.2. A slope
following this distribution is allocated randomly to each
participant. The time passing before a participant stops
the withdrawal is randomly allocated to each participant
as time is normally distributed with a mean of 8 weeks
and a standard deviation (SD) of 2 weeks in the placebo
g r o u pa n dam e a no f1 6w e e k sa n daS Do f2w e e k si n
the melatonin group. Finally, the dose at follow-up is
calculated for each participant.
Table 2 shows the mean and SD of dose at follow-up
in each intervention group according to this model. The
distributions are skewed and far from normal. They are
normalized with a square root transformation, but the
variances are still significantly different (see Table 2).
The larger of the two SDs (0.73) is used to compen-
sate for the inaccuracy of the estimates. With alfa =
0.05, beta = 0.1, and delta = 1.51 - 0.91 = 0.6, we esti-
mate a sample size for each group of 38. We round up
to 40 per intervention group.
As evident from the statistical analysis of the second-
ary outcomes, there might be other explanations for a
possible effect of melatonin, e.g. an accelerated rate of
discontinuation (increased slope) in the melatonin
group. But it seems reasonable to suggest a net effect,
which is approximately equivalent to the one gained by
improving the length of withdrawal with 2 months.
Furthermore, the baseline doses in the experimental
group may show to be somewhat higher than among
our previous outpatient sample. By adding 5 to all the
baseline doses and repeating the analysis, we get delta =
0.8 and SD = 0.65 which equals a sample size of 18 in
each group (the non-transformed means of follow-up
dose in the two groups are 3.92 and 1.39).
Consequently, a total sample size of 80 patients must
be regarded as a conservative estimate.
Discussion
This trial will assess if melatonin has a role in withdraw-
ing long-term benzodiazepine administration in patients
with schizophrenia. There is no other evidence-based
facilitating treatment and therefore the control group is
treated with placebo. Patients above 55 years are not
included in the trial because sleep characteristics and
cognitive abilities change markedly with increasing age
[46,47]. When discontinuing the use of benzodiazepines
the participants are relieved from the serious adverse
reactions associated with prolonged benzodiazepine
administration. Consequently, there is a substantial ther-
apeutic potential by conducting this trial both for the
individual participant as well as the future patients who
may gain advantage of the results. This group of
patients is difficult to treat and therefore often subject
to polypharmacy which may play a role in the reduced
life expectancy of patients compared with the back-
ground population [1,48]. The results will also bring
Table 2 Simulated data of benzodiazepine dose (mg
diazepam equivalents) at follow-up (in each intervention
group) to estimate the sample size (see text)
Group N Not transformed
Mean (SD)
Square root transformed
Mean (SD)
Placebo 99 2.81 (2.50) 1.51 (0.73)
Melatonin 99 1.09 (1.18) 0.91 (0.52)
Baseline dose 8.79 (6.50) 2.74 (1.13)
SD: Standard deviation.
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Page 8 of 11new information on the association of chronic benzodia-
zepine use with sleep, psychophysiology, cognition,
social function, and quality of life. Knowledge of these
important clinical aspects is lacking in this group of
patients.
Current status of trial
Inclusion is planned to begin in October 2011.
Appendix 1: Supplementary analyses of the
association of benzodiazepine withdrawal with
sleep, psychophysiology, cognition, social
function, quality of life, and other selected
variables
The participants in the SMART trial are difficult to recruit
and keep in the trial and therefore we wish to make thor-
ough use of the collected data. The SMART trial was
designed to evaluate differences between the two interven-
tion groups, i.e. differences between benzodiazepine with-
drawal under cover of prolonged-release melatonin versus
placebo. In addition to the analyses described in the proto-
col, we aim to analyze the whole study population from
baseline to follow-up, because we expect a larger effect
size on numerous of the assessed variables due to the ben-
zodiazepine dose reduction rather than the melatonin
treatment per se. For such an analysis we do not have a
control group (i.e. a group of participants not tapered off
from habitual benzodiazepine use). These supplementary
analyses will contribute with important knowledge on how
benzodiazepine dose reduction affects the selected vari-
ables in schizophrenia which will eventually lead to more
differentiated clinical treatment guidelines.
Hypotheses:
￿ Discontinuing or reducing the dose of long-term
benzodiazepine administration will result in
improved cognitive functioning reflected in positive
effects in the neurocognitive and psychophysiological
measures.
￿ Discontinuing or reducing the dose of long-term
benzodiazepine therapy will result in increased qual-
ity of life and subjective well-being due to elimi-
nated/reduced adverse reactions.
￿ Sleep continuity and sleep architecture will change
towards a more normal pattern when benzodiaze-
pine therapy is discontinued or reduced in dose - i.e.
reduced amount of stage 2 sleep, increased amount
of slow wave sleep and REM sleep (reversal of the
benzodiazepine induced changes), and improved
sleep efficiency.
￿ Discontinuing or reducing the dose of long-term
benzodiazepine therapy will result in improved social
functioning (due to eliminated/reduced adverse reac-
tions) but will not affect psychopathology.
Outcome measures (all variables listed below are eval-
uated with regard to the association with benzodiaze-
pine dose reduction/complete discontinuation for the
complete cohort of participants from baseline to follow-
up, controlled for a possible effect of melatonin):
￿ Psychophysiological measurements: primarily selec-
tive attention, secondarily sensory gating.
￿ Neurocognitive assessment: primarily BACS com-
posite score, secondarily BACS subscores.
￿ S l e e pc o n t i n u i t ya n ds l e e pa r c h i t e c t u r e( o n en i g h t
polysomnography): primarily sleep efficiency and
changes in sleep architecture, i.e. the percentage of
sleep spent in sleep stage 1, 2, 3+4, and REM. Sec-
ondarily, total sleep time, sleep latency, REM latency,
time awake after sleep onset, and number of
awakenings.
￿ Quality of life: WHO-5 Well-being Scale and Sub-
jective Well-being under neuroleptic treatment scale
(SWN-S) [49].
￿ Subjective assessment of sleep quality: primarily
Pittsburgh Sleep Quality Idex (PSQI) global score,
secondarily, PSQI subscores.
￿ Psychopathology: Positive and Negative Syndrome
Scale (PANSS) [50].
￿ Level of social functioning: Personal and Social
Performance Scale (PSP) [51].
￿ Clinical laboratory tests: fasting blood glucose, fast-
ing lipid panel, hematology, and serum chemistry
(sodium, potassium, creat i n i n e ,c a l c i u m ,a l a n i n e
transaminase, alkaline phosphatase, and international
normalized ratio).
￿ Lifestyle factors: smoking, physical exercise, and
alcohol and drug intake.
￿ Physical examination including blood pressure,
weight, height, waist circumference, and
electrocardiogram.
￿ Benzodiazepine withdrawal symptoms using the
Benzodiazepine Withdrawal Symptom Questionnaire
(BWSQ-2).
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